Comparison of two hormone replacement therapy schedules with 17 beta estradiol and micronized progesterone by oral route. Clinical evaluation, bleeding and lipids pattern and fibrinogen levels

This randomized controlled Trial evaluated the efficacy and tolerance of tw o different schedules of Hormonal Replacement Therapy (HRT) using oral micr onized 17 beta estradiol (valerate) (E2) 2 mg/day and oral Micronized Proge sterone (MP) 200 mg/day for 14 days each month (arm A) or each every three month (arm B). After 12 months of treatment, both schedules shown highly ab ility to decrease climacteric symptoms, offering predictable bleeding patte rn and antiatherogenic changes in lipid profile.